Eribulin (also called Halaven) has been rejected as the SMC did not consider the benefits provided by the drug justified the cost.
Eribulin is a chemotherapy drug used to treat advanced breast cancer. It works by stopping (inhibiting) the cancer cells from separating into two new cells, therefore blocking the growth of the cancer.
Eluned Hughes, Acting Director Scotland, Breast Cancer Now said: “We are disappointed that the SMC has declined yet another drug that could provide patient benefit and choice to women in Scotland living with secondary breast cancer.
“Today’s news is just one symptom of a much bigger issue; this is not only the third breast cancer drug that has been rejected since the SMC system was revised, but it is also the most inexpensive. As such, we are concerned about what this pattern means for secondary breast cancer overall; the pharmaceutical industry, and Governments across the UK must to work together to improve access to these life-extending drugs for patients.”